Literature DB >> 27401370

p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.

Bhushan Thakur1, Pritha Ray2.   

Abstract

Tumour suppressor p53, a master transcriptional regulator determines cell fate through preferential activation/repression of a myriad of genes during stress. Till date, activation and preferential binding of p53 on different promoters was reported to be influenced by the nature, strength and duration of stress which mediates its post translational modifications. Cisplatin, a widely used cytotoxic drug represses PIK3CA promoter activity and attenuates PI3K/AKT cell survival pathway through p53 activation in sensitive cells. However, very little is understood about the overall mechanism of p53-PIK3CA interaction and influence of p53 on the transcriptional status of PIK3CA during cisplatin resistance. Here we showed that cisplatin could dynamically alter p53 occupancy between the p53 binding sequences present in PIK3CA promoter in ovarian and breast cancer cells. This altered occupancy is dictated by higher acetylation and hyper-phosphorylation at serine 15, serine 20 and serine 46 residues. Interestingly, cisplatin resistant cells when challenged with cisplatin demonstrated abolished PIK3CA promoter attenuation, low level of p53 binding, and loss of p53 serine 46 phosphorylation. A phosphorylation deficient S46A mutant failed to repress PIK3CA in p53 deficient cells. Elevated expression of Bcl2, P27 and cFLIP indicated a pro-survival state in these resistant cells. Non-invasive real time imaging using two different luciferase reporters showed that cisplatin could simultaneously induce PIK3CA attenuation and p53 activation with growth regression in sensitive tumours but not in the resistant tumours where only low level of p53 activation and sustained growth was observed. This is the first report on phosphorylation of p53 serine 46 as a modulator of p53-PIK3CA promoter interaction which influences altered binding of p53 at different consensus sequences in the same promoter in response to chemotherapeutic stress. Absence of such modulation in resistant cellular milieu influences cellular homoeostasis in platinum-resistant cells probably due to altered post translational modification of p53.
Copyright © 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioluminescence imaging; PIK3CA; Post translational modification; p53

Mesh:

Substances:

Year:  2016        PMID: 27401370      PMCID: PMC5423208          DOI: 10.1016/j.molonc.2016.06.006

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  29 in total

Review 1.  Post-translational modifications and activation of p53 by genotoxic stresses.

Authors:  E Appella; C W Anderson
Journal:  Eur J Biochem       Date:  2001-05

Review 2.  To repress or not to repress: this is the guardian's question.

Authors:  John L Rinn; Maite Huarte
Journal:  Trends Cell Biol       Date:  2011-05-19       Impact factor: 20.808

Review 3.  Transcriptional regulation by p53.

Authors:  Rachel Beckerman; Carol Prives
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-28       Impact factor: 10.005

4.  Kinetics of p53 binding to promoter sites in vivo.

Authors:  S T Szak; D Mays; J A Pietenpol
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

5.  Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.

Authors:  Lindsey D Mayo; Young Rok Seo; Mark W Jackson; Martin L Smith; Javier Rivera Guzman; Chandrashekhar K Korgaonkar; David B Donner
Journal:  J Biol Chem       Date:  2005-04-20       Impact factor: 5.157

Review 6.  p53 post-translational modification: deregulated in tumorigenesis.

Authors:  Chao Dai; Wei Gu
Journal:  Trends Mol Med       Date:  2010-11       Impact factor: 11.951

7.  The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.

Authors:  A Astanehe; M R Finkbeiner; P Hojabrpour; K To; A Fotovati; A Shadeo; A L Stratford; W L Lam; I M Berquin; V Duronio; S E Dunn
Journal:  Oncogene       Date:  2009-05-11       Impact factor: 9.867

8.  A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.

Authors:  M Kracikova; G Akiri; A George; R Sachidanandam; S A Aaronson
Journal:  Cell Death Differ       Date:  2013-01-11       Impact factor: 15.828

Review 9.  The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.

Authors:  Bianca Cheaib; Aurélie Auguste; Alexandra Leary
Journal:  Chin J Cancer       Date:  2015-01

10.  High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity.

Authors:  Alessia Garufi; Gabriella D'Orazi
Journal:  J Exp Clin Cancer Res       Date:  2014-09-27
View more
  8 in total

1.  p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.

Authors:  Bhushan Thakur; Pritha Ray
Journal:  Mol Oncol       Date:  2016-06-29       Impact factor: 6.603

2.  Molecular markers of DNA damage and repair in cervical cancer patients treated with cisplatin neoadjuvant chemotherapy: an exploratory study.

Authors:  Nilda E Real; Gisela N Castro; F Darío Cuello-Carrión; Claudia Perinetti; Hanna Röhrich; Niubys Cayado-Gutiérrez; Martin E Guerrero-Gimenez; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2017-06-12       Impact factor: 3.667

3.  Large Cell Neuroendocrine Carcinoma Shares Similarity with Small Cell Carcinoma on the Basis of Clinical and Pathological Features.

Authors:  Fengkai Xu; Ke Chen; Chunlai Lu; Jie Gu; Haiying Zeng; Yifan Xu; Yuan Ji; Di Ge
Journal:  Transl Oncol       Date:  2019-02-25       Impact factor: 4.243

4.  Molecular imaging of the kinetics of hyperactivated ERK1/2-mediated autophagy during acquirement of chemoresistance.

Authors:  Aniketh Bishnu; Pratham Phadte; Ajit Dhadve; Asmita Sakpal; Bharat Rekhi; Pritha Ray
Journal:  Cell Death Dis       Date:  2021-02-08       Impact factor: 8.469

Review 5.  Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.

Authors:  Tao Guo; Xue Dong; Shanli Xie; Ling Zhang; Peibin Zeng; Lin Zhang
Journal:  Cancer Manag Res       Date:  2021-04-08       Impact factor: 3.989

6.  A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin.

Authors:  Nupur Mukherjee; Alacoque Browne; Laura Ivers; Tapesh Santra; Mattia Cremona; Bryan T Hennessy; Norma O'Donovan; John Crown; Walter Kolch; Dirk Fey; Alex J Eustace
Journal:  J Pers Med       Date:  2022-08-03

7.  Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop.

Authors:  Bhushan Thakur; Pritha Ray
Journal:  J Exp Clin Cancer Res       Date:  2017-11-23

8.  Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.

Authors:  Weiwei Liu; Lu Zheng; Rongguiyi Zhang; Ping Hou; Jiakun Wang; Linquan Wu; Jing Li
Journal:  Mol Cancer       Date:  2022-03-11       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.